Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
An Obama-era policy to increase accountability for individuals accused of corporate wrongdoing still applies at the Department of Justice, an assistant U.S. attorney said June 6.
Margaret L. Hutchinson, who leads the civil division for the U.S. Attorney’s Office in the Eastern District of Pennsylvania, said the 2015 policy known as the “ Yates memo” has implications for how the DOJ assesses research noncompliance allegations under the False Claims Act.
“We must now follow the Yates memo,” Hutchinson said at a conference. “It’s still in place, and it’s still in effect.”
The memo is named after its author, former Acting Attorney General Sally Yates, whom President Donald Trump fired Jan. 30 after she advised Justice attorneys not to follow the president’s executive order on immigration. Yates issued the memo in September 2015 to describe steps the DOJ should take when investigating cases of corporate misconduct. The memo reflected a policy shift that said in part, “criminal and civil corporate investigations should focus on individuals from the inception of the investigation.”
Hutchinson’s remarks, which she said were her own views and didn’t represent the DOJ, were in response to a question at the Health Care Compliance Association’s research compliance conference in Baltimore about how the DOJ assesses compliance programs in the research arena, especially as it dovetails with the Yates memo.
“We must now look at individuals and see if they also could be exposed to and liable under the False Claims Act in addition to looking at the institution,” Hutchinson said. “That has definitely affected our investigations—most definitely. We are not now as quick to resolve and settle cases with the institution.”
The Yates memo can serve as a valuable tool for research compliance officers, Hutchinson told the conference attendees, in making the case about the importance of a robust compliance program.
“You can say to your institutions, I’m not just [saying] this because the institution’s going to have exposure. I’m [saying it] because you individuals may have exposure,” she said.
The False Claims Act imposes liability on anyone who:
“It’s extraordinarily broad,” she said, “It’s not just a fee for service, but it’s the actual draw down on the research grant itself. Each time there’s a draw down, that is perceived as a claim for False Claims Act liability purposes.”
Under an amendment implemented a few years ago, Hutchinson said, the scope of false claims now includes liability on improper retention of an overpayment.
“In the 2017 version of the False Claims Act,” she said, there is “liability if you later determine that what you got, you shouldn’t have gotten, and you don’t refund it.”
In addition to directly submitting a false claim to the federal government, Hutchinson said causing the submission of a false claim also triggers liability under the statute. Most research-related FCA cases stem from the misuse of research that results in the submission of a false claim, she said.
“This kind of research fraud is what we work with often,” she said. These cases include misusing or misreporting research to justify approval of or payment for a medical device or pharmaceutical product that the government otherwise would not have authorized.
“We’re not scientists. We don’t play scientists on TV. We don’t pretend to be scientists. We use scientific information to improve our health care and to pay for our health care,” Hutchinson said. “And we need to be able to rely on the integrity of that science. And when we can’t, then the Department of Justice and the False Claims Act come into play.”
The DOJ pursues FCA cases via a number of avenues, including whistleblowers, state false-claims cases, class action lawsuits, and inspection reports. Hutchinson said she looks forward to the Work Plan the Health and Human Services Office of Inspector General releases every year.
“I love to see what they’re going to audit next. And I love to see what they’re going to find,” she said, noting the HHS inspector general makes findings but not conclusions.
“They find there was $5 million mispaid by [an institution], but they’re not saying it’s fraud,” Hutchinson said. “But then we come and say, ‘Yeah, but we’re saying it’s fraud.’”
The work of research compliance offices and other movements to increase the transparency of health care and research—such as the Open Payments program at the Centers for Medicare & Medicaid Services that requires institutions to disclose payments to doctors from drug and device companies—are working, she said.
“We are seeing an improvement,” Hutchinson said, “but I think we still have a lot to do.”
To contact the reporter on this story: Jeannie Baumann in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)